



PTO/SB/08A (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 17 Sheets

### Complete if Known

Application Number	10/798,896
Filing Date	03/11/2004
First Named Inventor	Draghia-Akli, et al.
Group Art Unit	1632
Examiner Name	Paul Powell
Attorney Docket Number	AVSI-0034 (108328.00172)

### U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
pn	1	U.S.- 4,683,202	28-Jul-87	Mullis	Entire Patent
	2	U.S.- 4,956,288	11-Sep-90	Barsoum	Entire Patent
	3	U.S.- 5,298,422	29-Mar-94	Schwartz	Entire Patent
	4	U.S.- 5,374,544	20-Dec-94	Schwartz	Entire Patent
	5	U.S.- 5,384,253	24-Jan-95	Krzyzck	Entire Patent
	6	U.S.- 5,439,440	08-Aug-95	Hofmann	Entire Patent
	7	U.S.- 5,702,384	30-Dec-97	Umeyama	Entire Patent
	8	U.S.- 5,704,908	06-Jan-98	Hofmann	Entire Patent
	9	U.S.- 5,756,264	26-May-98	Schwartz	Entire Patent
	10	U.S.- 5,925,564	20-Jul-99	Schwartz	Entire Patent
	11	U.S.- 5,925,565	20-Jul-99	Berlioz	Entire Patent
	12	U.S.- 5,928,906	27-Jul-99	Koster	Entire Patent
	13	U.S.- 5,935,819	10-Aug-99	Eichner	Entire Patent
	14	U.S.- 5,955,365	21-Sep-99	Szoka	Entire Patent
	15	U.S.- 6,150,168	21-Nov-00	Woo	Entire Patent
pn	16	U.S.- 6,177,554	23-Jan-01	Woo	Entire Patent

### FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				

Examiner Signature

Date Considered

3/14/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 17 Sheets

**Complete if Known**

Application Number	10798,896
Filing Date	03/11/2004
First Named Inventor	Draghla-Akli, et al.
Group Art Unit	1632
Examiner Name	PAUL DOWE
Attorney Docket Number	AVSI-0034 (108328.00172)

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PD	17	AIHARA, H. and J. Miyazaki. 1998. Gene transfer into muscle by electroporation in vivo. Nat. Biotechnol. 16:867-870.	
	18	AKENO, N., J. Robins, M. Zhang, M. F. Czyzyk-Krzeska, and T. L. Clemens. 2002. Induction of vascular endothelial growth factor by IGF-I in osteoblast-like cells is mediated by the PI3K signaling pathway through the hypoxia-inducible factor-2alpha. Endocrinology 143:420-425.	
	19	ALILA, H., M. Coleman, H. Nitta, M. French, K. Anwer, Q. Liu, T. Meyer, J. Wang, R. Mumper, D. Oubari, S. Long, J. Nordstrom, and A. Rolland. 1997. Expression of biologically active human insulin-like growth factor-I following intramuscular injection of a formulated plasmid in rats. Hum. Gene Ther. 8:1785-1795.	
	20	ALMENDRO, N., T. Bellon, C. Rius, P. Lastres, C. Langa, A. Corbi, and C. Bernabeu. 1996. Cloning of the human platelet endothelial cell adhesion molecule-1 promoter and its tissue-specific expression. Structural and functional characterization. J. Immunol. 157:5411-5421.	
	21	ANDRES, V. and K. Walsh. 1996. Myogenin expression, cell cycle withdrawal, and phenotypic differentiation are temporally separable events that precede cell fusion upon myogenesis. J Cell Biol. 132:657-666.	
	22	ARATANI, Y., R. Okazaki, and H. Koyama. 1992. End extension repair of introduced targeting vectors mediated by homologous recombination in mammalian cells. Nucleic Acids Res. 20:4795-4801.	
	23	ARTHUR, W. T., R. B. Vernon, E. H. Sage, and M. J. Reed. 1998. Growth factors reverse the impaired sprouting of microvessels from aged mice. Microvasc. Res. 55:260-270.	
	24	BAGUST, A., P. K. Hopkinson, L. Maslove, and C. J. Currie. 2002. The projected health care burden of Type 2 diabetes in the UK from 2000 to 2060. Diabet. Med. 19 Suppl 4:1-5:1-5.	
	25	BARTON-DAVIS, E. R., D. I. Shoturma, A. Musaro, N. Rosenthal, and H. L. Sweeney. 1998. Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function [In Process Citation]. Proc. Natl. Acad. Sci. U. S. A. 95:15603-15607.	
PD	26	BECKMAN, J.A., Creager, M.A., Libby, P., 2002. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287, 2570-2581.	

Examiner  
SignatureDate  
Considered

3/14/2006

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 17 Sheets

**Complete if Known**

Application Number	10/798,896
Filing Date	03/11/2004
First Named Inventor	Draghla-Akli, et al
Group Art Unit	1632
Examiner Name	PAUL DOWELL
Attorney Docket Number	AVSI-0034 (108328.00172)

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PD	27	BERMONT, L., F. Lamielle, S. Fauconnet, H. Esumi, A. Weisz, and G. L. Adessi. 2000. Regulation of vascular endothelial growth factor expression by insulin-like growth factor-I in endometrial adenocarcinoma cells. <i>Int. J. Cancer</i> 85:117-123.	
	28	BETTAN, M., F. Emmanuel, R. Dartail, J. M. Caillaud, F. Soubrier, P. Delaere, D. Branelec, A. Mahfoudi, N. Duverger, and D. Scherman. 2000. High-level protein secretion into blood circulation after electric pulse-mediated gene transfer into skeletal muscle. <i>Mol. Ther.</i> 2:204-210.	
	29	BOSHART, M., F. Weber, G. Jahn, K. Dorsch-Hasler, B. Fleckenstein, and W. Schaffner. 1985. A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. <i>Cell</i> 41:521-530.	
	30	BUERKE, M., T. Murohara, C. Skurk, C. Nuss, K. Tomaselli, and A. M. Lefer. 1995. Cardioprotective effect of insulin-like growth factor I in myocardial ischemia followed by reperfusion. <i>Proc. Natl. Acad. Sci. U. S. A</i> 92:8031-8035.	
	31	CARBONELLI, D. L., E. Corley, M. Seigelchifer, and J. Zorzopulos. 1999. A plasmid vector for isolation of strong promoters in <i>Escherichia coli</i> . <i>FEMS Microbiol. Lett.</i> 177:75-82.	
	32	CARONI, P., C. Schneider, M. C. Kiefer, and J. Zapf. 1994. Role of muscle insulin-like growth factors in nerve sprouting: suppression of terminal sprouting in paralyzed muscle by IGF-binding protein 4. <i>J. Cell Biol.</i> 125:893-902.	
	33	CASTELLON, R., H. K. Hamdi, I. Sacerio, A. M. Aoki, M. C. Kenney, and A. V. Ljubimov. 2002. Effects of angiogenic growth factor combinations on retinal endothelial cells. <i>Exp. Eye Res.</i> 74:523-535.	
	34	CHANDLER, S. D., A. Mayeda, J. M. Yeakley, A. R. Krainer, and X. D. Fu. 1997. RNA splicing specificity determined by the coordinated action of RNA recognition motifs in SR proteins. <i>Proc. Natl. Acad. Sci. U. S. A</i> 94:3596-3601.	
	35	CHENG, H. L., A. Randolph, D. Yee, P. Delafontaine, G. Tennekoon, and E. L. Feldman. 1996. Characterization of insulin-like growth factor-I and its receptor and binding proteins in transected nerves and cultured Schwann cells. <i>J. Neurochem.</i> 66:525-536.	
PD	36	COCEA, L. 1997. Duplication of a region in the multiple cloning site of a plasmid vector to enhance cloning-mediated addition of restriction sites to a DNA fragment. <i>Biotechniques</i> 23:814-816.	

Examiner  
SignatureDate  
Considered

3/14/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 17 Sheets

**Complete if Known**

Application Number	10/798,896
Filing Date	03/11/2004
First Named Inventor	Draghia-Akli, et al.
Group Art Unit	1632
Examiner Name	Paul M. Miller
Attorney Docket Number	AVSI-0034 (108328.00172)

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PD	37	COLEMAN, M. E., F. DeMayo, K. C. Yin, H. M. Lee, R. Geske, C. Montgomery, and R. J. Schwartz. 1995. Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. J. Biol. Chem. 270:12109-12116.	
	38	CRUQUIM, H., 2001. Peripheral arterial disease—epidemiological aspects. Vasc. Med. 6, 3-7.	
	39	CURRIE, C. J., C. L. Morgan, and J. R. Peters. 1998. The epidemiology and cost of inpatient care for peripheral vascular disease, infection, neuropathy, and ulceration in diabetes. Diabetes Care 21:42-48.	
	40	DAI, B., H. Wu, E. Holthuisen, and P. Singh. 2001. Identification of a novel cis element required for cell density-dependent down-regulation of insulin-like growth factor-2 P3 promoter activity in Caco2 cells. J. Biol. Chem. 276:6937-6944.	
	41	DANKO, I. and J. A. Wolff. 1994. Direct gene transfer into muscle. [Review]. Vaccine 12:1499-1502.	
	42	DARQUET, A. M., B. Cameron, P. Wils, D. Scherman, and J. Crouzet. 1997. A new DNA vehicle for nonviral gene delivery: supercoiled minicircle. Gene Ther. 4:1341-1349.	
	43	DARQUET, A. M., R. Rangara, P. Kreiss, B. Schwartz, S. Naimi, P. Delaere, J. Crouzet, and D. Scherman. 1999. Minicircle: an improved DNA molecule for in vitro and in vivo gene transfer. Gene Ther. 6:209-218.	
	44	DAVIS, H. L., R. G. Whalen, and B. A. Demencix. 1993. Direct gene transfer into skeletal muscle in vivo: factors affecting efficiency of transfer and stability of expression. Human Gene Therapy 4:151-159.	
	45	DAVIS, S., N. Papadopoulos, T. H. Aldrich, P. C. Maisonpierre, T. Huang, L. Kovac, A. Xu, R. Leidich, E. Radziejewska, A. Rafique, J. Goldberg, V. Jain, K. Bailey, M. Karow, J. Fandl, S. J. Samuelsson, E. Ioffe, J. S. Rudge, T. J. Daly, C. Radziejewski, and G. D. Yancopoulos. 2003. Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering. Nat. Struct. Biol. 10:38-44.	
	46	DE LUCA, A., S. Pierno, C. Camerino, D. Cocchi, and D. C. Camerino. 1999. Higher content of insulin-like growth factor-I in dystrophic mdx mouse: potential role in the spontaneous regeneration through an electrophysiological investigation of muscle function. Neuromuscul. Disord. 9:11-18.	

Examiner  
SignatureDate  
Considered

3/14/2004

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>2</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 17 Sheets

**Complete if Known**

Application Number	10798,896
Filing Date	03/11/2004
First Named Inventor	Draghia-Akli, et al.
Group Art Unit	1632
Examiner Name	PAUL POWELL
Attorney Docket Number	AVSI-0034 (108328.00172)

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PO	47	DOLNIK, V., M. Novotny, and J. Chmelik. 1993. Electromigration behavior of poly-(L-glutamate) conformers in concentrated polyacrylamide gels. Biopolymers 33:1299-1306.	
	48	DONATH, M. Y., M. A. Gosteli-Peter, C. Hauri, E. R. Froesch, and J. Zapf. 1997. Insulin-like growth factor-I stimulates myofibrillar genes and modulates atrial natriuretic factor mRNA in rat heart. Eur. J. Endocrinol. 137:309-315.	
	49	DONATH, M. Y., G. Sutsch, X. W. Yan, B. Piva, H. P. Brunner, Y. Glatz, J. Zapf, F. Follath, E. R. Froesch, and W. Kiowski. 1998. Acute cardiovascular effects of insulin-like growth factor I in patients with chronic heart failure. J. Clin. Endocrinol. Metab 83:3177-3183.	
	50	DONATH, M. Y., J. Zapf, M. Eppenberger-Eberhardt, E. R. Froesch, and H. M. Eppenberger. 1994. Insulin-like growth factor I stimulates myofibril development and decreases smooth muscle alpha-actin of adult cardiomyocytes. Proc. Natl. Acad. Sci. U. S. A 91:1686-1690.	
	51	DORSCH-HASLER, K., G. M. Keil, F. Weber, M. Jasin, W. Schaffner, and U. H. Koszinowski. 1985. A long and complex enhancer activates transcription of the gene coding for the highly abundant immediate early mRNA in murine cytomegalovirus. Proc. Natl. Acad. Sci. U. S. A 82:8325-8329.	
	52	DRAGHIA-Akli, R., M. L. Fiorotto, L. A. Hill, P. B. Malone, D. R. Deaver, and R. J. Schwartz. 1999. Myogenic expression of an injectable protease-resistant growth hormone-releasing hormone augments long-term growth in pigs. Nat. Biotechnol. 17:1179-1183.	
	53	DRAGHIA-Akli, R., A. S. Khan, K. K. Cummings, D. Parghi, R. H. Carpenter, and P. A. Brown. 2002a. Electrical Enhancement of Formulated Plasmid Delivery in Animals. Technology in Cancer Research & Treatment 1:365-371.	
	54	DRAGHIA-Akli, R., P. B. Malone, L. A. Hill, K. M. Ellis, R. J. Schwartz, and J. L. Nordstrom. 2002. Enhanced animal growth via ligand-regulated GHRH myogenic-injectable vectors. FASEB J. 16:426-428.	
PO	55	FEENER, E. P. and G. L. King. 1997. Vascular dysfunction in diabetes mellitus. Lancet 350 Suppl 1:S19-13.:S19-13.	

Examiner  
SignatureDate  
Considered

3/14/2006

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 6 of 17 Sheets

**Complete If Known**

Application Number	10/798,896
Filing Date	03/11/2004
First Named Inventor	Draghia-Akli, et al.
Group Art Unit	1632
Examiner Name	PAUL DANIEL
Attorney Docket Number	AVSI-0034 (108328.00172)

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PD	56	FEWELL, J. G., F. MacLaughlin, V. Mehta, M. Gondo, F. Nicol, E. Wilson, and L. C. Smith. 2001. Gene therapy for the treatment of hemophilia B using PINC-formulated plasmid delivered to muscle with electroporation. Mol. Ther. 3:574-583.	
	57	FIORRELLI, G., L. Formigli, O. S. Zecchi, F. Gori, A. Falchetti, A. Morelli, A. Tanini, S. Benvenuti, and M. L. Brandi. 1996. Characterization and function of the receptor for IGF-I in human preosteoclastic cells. Bone 18:269-276.	
	58	FIORRELLI, G., C. Orlando, S. Benvenuti, F. Franceschelli, S. Bianchi, P. Pioli, A. Tanini, M. Serio, F. Bartucci, and M. L. Brandi. 1994. Characterization, regulation, and function of specific cell membrane receptors for insulin-like growth factor I on bone endothelial cells. J Bone Miner. Res. 9:329-337.	
	59	FLAMME, I., G. Breier, and W. Risau. 1995. Vascular endothelial growth factor (VEGF) and VEGF receptor 2 (Flk-1) are expressed during vasculogenesis and vascular differentiation in the quail embryo. Dev. Biol. 169:699-712.	
	60	FLORINI, J. R., D. Z. Ewton, K. A. Magri, and F. J. Mangiacapra. 1993. IGFs and muscle differentiation. Adv. Exp. Med. Biol. 343:319-26:319-326.	
	61	FLORINI, J. R., K. A. Magri, D. Z. Ewton, P. L. James, K. Grindstaff, and P. S. Rotwein. 1991. "Spontaneous" differentiation of skeletal myoblasts is dependent upon autocrine secretion of insulin-like growth factor-II. J. Biol. Chem. 266:15917-15923.	
	62	FOLKMAN, J. and M. Klagsbrun. 1987. Angiogenic factors. Science 235:442-447.	
	63	FOWLER, B., Jamrozik, K., Norman, P., Allen, Y., 2002. Prevalence of peripheral arterial disease: persistence of excess risk in former smokers. Aust. N. Z. J Public Health 26, 219-224.	
PD	64	FRYER, A. D. and D. B. Jacoby. 1993. Effect of inflammatory cell mediators on M2 muscarinic receptors in the lungs. Life Sci. 52:529-536.	

Examiner  
SignatureDate  
Considered

3/14/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 7 of 17 Sheets

**Complete If Known**

Application Number	10/798,896
Filing Date	03/11/2004
First Named Inventor	Draghia-Akli, Ruxandra
Group Art Unit	1632
Examiner Name	PAUL BOWEN
Attorney Docket Number	AVSI-0034 (108328.00172)

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PD	65	GEHL, J., T. Skovsgaard, and L. M. Mir. 1998. Enhancement of cytotoxicity by electroporation: an improved method for screening drugs. <i>Anticancer Drugs</i> 9:319-325.	
	66	GEHL, J., T. H. Sorensen, K. Nielsen, P. Raskmark, S. L. Nielsen, T. Skovsgaard, and L. M. Mir. 1999. In vivo electroporation of skeletal muscle: threshold, efficacy and relation to electric field distribution. <i>Biochim. Biophys. Acta</i> 1428:233-240.	
	67	GERMAN, M., S. Ashcroft, K. Docherty, H. Edlund, T. Edlund, S. Goodison, H. Imura, G. Kennedy, O. Madsen, D. Melloul, and . 1995. The insulin gene promoter. A simplified nomenclature. <i>Diabetes</i> 44:1002-1004.	
	68	GLAZNER, G. W., A. E. Morrison, and D. N. Ishii. 1994. Elevated insulin-like growth factor (IGF) gene expression in sciatic nerves during IGF-supported nerve regeneration. <i>Brain Res. Mol. Brain Res.</i> 25:265-272.	
	69	GOAD, D. L., J. Rubin, H. Wang, A. H. Tashjian, Jr., and C. Patterson. 1996. Enhanced expression of vascular endothelial growth factor in human SaOS-2 osteoblast-like cells and murine osteoblasts induced by insulin-like growth factor I. <i>Endocrinology</i> 137:2262-2268.	
	70	GOLDSPINK, G. 1999. Changes in muscle mass and phenotype and the expression of autocrine and systemic growth factors by muscle in response to stretch and overload. <i>J. Anat.</i> 194:323-334.	
	71	HELLER, R., M. J. Jaroszeski, L. F. Glass, J. L. Messina, D. P. Rapaport, R. C. DeConti, N. A. Fenske, R. A. Gilbert, L. M. Mir, and D. S. Reintgen. 1996. Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy. <i>Cancer</i> 77:964-971.	
	72	HERZOG, R. W., J. D. Mount, V. R. Arruda, K. A. High, and C. D. Lothrop, Jr. 2001. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. <i>Mol. Ther.</i> 4:192-200.	
	73	HORLICK, R. A. and P. A. Benfield. 1989. The upstream muscle-specific enhancer of the rat muscle creatine kinase gene is composed of multiple elements. <i>Mol. Cell Biol.</i> 9:2396-2413.	
	74	HORVATH, K. A., J. Doukas, C. Y. Lu, N. Belkind, R. Greene, G. F. Pierce, and D. A. Fullerton. 2002. Myocardial functional recovery after fibroblast growth factor 2 gene therapy as assessed by echocardiography and magnetic resonance imaging. <i>Ann. Thorac. Surg.</i> 74:481-486.	

Examiner  
SignatureDate  
Considered

3/14/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 8 of 17 Sheets

**Complete if Known**

Application Number	10/798,896
Filing Date	03/11/2004
First Named Inventor	Draghia-Akli, et al
Group Art Unit	1632
Examiner Name	PAUL DOWELL
Attorney Docket Number	AVSI-0034 (108328.00172)

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PD	75	HSU, H. H., M. M. Zdanowicz, V. R. Agarwal, and P. W. Speiser. 1997. Expression of myogenic regulatory factors in normal and dystrophic mice: effects of IGF-I treatment. Biochem. Mol. Med. 60:142-148.	
	76	INOUE, C., P. Remondelli, M. Karin, and S. Elledge. 1994. Isolation of a cDNA encoding a metal response element binding protein using a novel expression cloning procedure: the one hybrid system. DNA Cell Biol. 13:731-742.	
	77	INOUE, S., A. Nakazawa, and T. Nakazawa. 1985. Determination of the transcription initiation site and identification of the protein product of the regulatory gene xylR for xyl operons on the TOL plasmid. J. Bacteriol. 163:863-869.	
	78	ITO, H., M. Hiroe, Y. Hirata, M. Tsujino, S. Adachi, M. Shichiri, A. Koike, A. Nogami, and F. Marumo. 1993. Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes. Circulation 87:1715-1721.	
	79	JABRI, N., D. S. Schalch, S. L. Schwartz, J. S. Fischer, M. S. Kipnes, B. J. Radnik, N. J. Turman, V. S. Marcsisin, and H. P. Guler. 1994. Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients. Diabetes 43:369-374.	
	80	JAYNES, J. B., J. E. Johnson, J. N. Buskin, C. L. Gartside, and S. D. Hauschka. 1988. The muscle creatine kinase gene is regulated by multiple upstream elements, including a muscle-specific enhancer. Mol. Cell Biol. 8:62-70.	
	81	JESCHKE, M. G., R. E. Barrow, H. K. Hawkins, K. Yang, R. L. Hayes, B. J. Lichtenbelt, J. R. Perez-Polo, and D. N. Herndon. 1999. IGF-I gene transfer in thermally injured rats. Gene Ther. 6:1015-1020.	
	82	Kardami, E. 1990. Stimulation and inhibition of cardiac myocyte proliferation in vitro. Mol. Cell Biochem. 92:129-135.	
PD	83	Kasemkijwattana, C., J. Menetrey, G. Somogyi, M. S. Moreland, F. H. Fu, B. Buranapanitkit, S. C. Watkins, and J. Huard. 1998. Development of approaches to improve the healing following muscle contusion. Cell Transplant. 7:585-598.	

Examiner  
SignatureDate  
Considered

3/14/2004

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 9 of 17 Sheets

**Complete If Known**

Application Number	10/798,896
Filing Date	03/11/2004
First Named Inventor	Draghia-Akli, Ruxandra
Group Art Unit	
Examiner Name	
Attorney Docket Number	AVSI-0034 (108328.00172)

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
M	84	KAWAMOTO, T., K. Makino, H. Niwa, H. Sugiyama, S. Kimura, M. Amemura, A. Nakata, and T. Kakunaga. 1988. Identification of the human beta-actin enhancer and its binding factor. Mol. Cell Biol. 8:267-272.	
	85	KAWAMOTO, T., K. Makino, S. Orita, A. Nakata, and T. Kakunaga. 1989. DNA bending and binding factors of the human beta-actin promoter. Nucleic Acids Res. 17:523-537.	
	86	KLAMUT, H. J., L. O. Bosnoyan-Collins, R. G. Worton, P. N. Ray, and H. L. Davis. 1996. Identification of a transcriptional enhancer within muscle intron 1 of the human dystrophin gene. Hum. Mol. Genet. 5:1599-1606.	
	87	KLAMUT, H. J., S. B. Gangopadhyay, R. G. Worton, and P. N. Ray. 1990. Molecular and functional analysis of the muscle-specific promoter region of the Duchenne muscular dystrophy gene. Mol. Cell Biol. 10:193-205.	
	88	KRAUS, J., M. Wolte, N. Schonwetter, and V. Holth. 1998. Alternative promoter usage and tissue specific expression of the mouse somatostatin receptor 2 gene. FEBS Lett. 428:165-170.	
P	89	LAREYRE, J. J., T. Z. Thomas, W. L. Zheng, S. Kasper, D. E. Ong, M. C. Orgebin-Crist, and R. J. Matusik. 1999. A 5-kilobase pair promoter fragment of the murine epididymal retinoic acid-binding protein gene drives the tissue-specific, cell-specific, and androgen-regulated expression of a foreign gene in the epididymis of transgenic mice. J. Biol. Chem. 274:8282-8290.	
	90	LARSEN, P. R., J. W. Harney, and D. D. Moore. 1986. Sequences required for cell-type specific thyroid hormone regulation of rat growth hormone promoter activity. J. Biol. Chem. 261:14373-14376.	
	91	LEE, S. H., W. Wang, S. Yajima, P. A. Jose, and M. M. Mouradian. 1997. Tissue-specific promoter usage in the D1A dopamine receptor gene in brain and kidney. DNA Cell Biol. 16:1267-1275.	

Examiner  
SignatureDate  
Considered

3/14/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 10 of 17 Sheets

**Complete if Known**

Application Number	10798,896
Filing Date	03/11/2004
First Named Inventor	Draghia-Akli, et al.
Group Art Unit	1632
Examiner Name	PAUL ROVERE
Attorney Docket Number	AVSI-0034 (108328.00172)

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PD	92	Lesbordes, J. C., T. Bordet, G. Haase, L. Castelnau-Ptakhine, S. Rouhani, H. Gilgenkrantz, and A. Kahn. 2002. In vivo electroporation of the cardiotrophin-1 gene into skeletal muscle slows down progression of motor neuron degeneration in pmn mice. Hum. Mol. Genet. 11:1615-1625.	
	93	LESCAUDRON, L., E. Peltekian, J. Fontaine-Perus, D. Paulin, M. Zampieri, L. Garcia, and E. Parrish. 1999. Blood borne macrophages are essential for the triggering of muscle regeneration following muscle transplant. Neuromuscul. Disord. 9:72-80.	
	94	LEUNG, D. W., G. Cachianes, W. J. Kuang, D. V. Goeddel, and N. Ferrara. 1989. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306-1309.	
	95	LEVENSON, V. V., E. D. Transue, and I. B. Roninson. 1998. Internal ribosomal entry site-containing retroviral vectors with green fluorescent protein and drug resistance markers. Hum. Gene Ther. 9:1233-1236.	
	96	LI, C., S. Ke, Q. P. Wu, W. Tansey, N. Hunter, L. M. Buchmiller, L. Milas, C. Chamsangavej, and S. Wallace. 2000. Tumor irradiation enhances the tumor-specific distribution of poly(L-glutamic acid)-conjugated paclitaxel and its antitumor efficacy. Clin. Cancer Res. 6:2829-2834.	
	97	LI, X., E. M. Eastman, R. J. Schwartz, and R. Draghia-Akli. 1999. Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences. Nat. Biotechnol. 17:241-245.	
	98	LIN, H., K. E. Yutzey, and S. F. Konieczny. 1991. Muscle-specific expression of the troponin I gene requires interactions between helix-loop-helix muscle regulatory factors and ubiquitous transcription factors. Mol. Cell Biol. 11:267-280.	
	99	LIU, Y., H. Li, K. Tanaka, N. Tsumaki, and Y. Yamada. 2000. Identification of an enhancer sequence within the first intron required for cartilage-specific transcription of the alpha2(XI) collagen gene. J. Biol. Chem. 275:12712-12718.	
	100	LOMBARDI, G., A. Colao, A. Cuocolo, S. Longobardi, C. Di Somma, F. Orio, B. Merola, E. Nicolai, and M. Salvatore. 1997. Cardiological aspects of growth hormone and insulin-like growth factor-I. J. Pediatr. Endocrinol. Metab 10:553-560.	
PD	101	LUCAS, M. L., L. Heller, D. Coppola, and R. Heller. 2002. IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Mol. Ther. 5:668-675.	

Examiner  
SignatureDate  
Considered

3/14/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 11 of 17 Sheets

**Complete If Known**

Application Number	10/798,896
Filing Date	03/11/2004
First Named Inventor	Draghia-Akli, et al.
Group Art Unit	1632
Examiner Name	PAUL DOWELL
Attorney Docket Number	AVSI-0034 (108328.00172)

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PD	102	LUCAS, M. L., M. J. Jaroszeski, R. Gilbert, and R. Heller. 2001. In vivo electroporation using an exponentially enhanced pulse: a new waveform. DNA Cell Biol. 20:183-188.	
	103	MACCOLL, G. S., G. Goldspink, and P. M. Bouloux. 1999. Using skeletal muscle as an artificial endocrine tissue. J. Endocrinol. 162:1-9.	
	104	MACEJAK, D. G. and P. Sarnow. 1991. Internal initiation of translation mediated by the 5' leader of a cellular mRNA. Nature 353:90-94.	
	105	MATSUBARA, H., Y. Gunji, T. Maeda, K. Tasaki, Y. Koide, T. Asano, T. Ochiai, S. Sakiyama, and M. Tagawa. 2001. Electroporation-mediated transfer of cytokine genes into human esophageal tumors produces anti-tumor effects in mice. Anticancer Res. 21:2501-2503.	
	106	MATSUO, A., I. Tooyama, S. Isobe, Y. Oomura, I. Akiguchi, K. Hanai, J. Kimura, and H. Kimura. 1994. Immunohistochemical localization in the rat brain of an epitope corresponding to the fibroblast growth factor receptor-1. Neuroscience 60:49-66.	
	107	MCNALLY, M. A., J. S. Lebkowski, T. B. Okarma, and L. B. Lerch. 1988. Optimizing electroporation parameters for a variety of human hematopoietic cell lines. Biotechniques 6:882-886.	
	108	MEIGS, J. B., M. G. Larson, R. B. D'Agostino, D. Levy, M. E. Clouse, D. M. Nathan, P. W. Wilson, and C. J. O'Donnell. 2002. Coronary artery calcification in type 2 diabetes and insulin resistance: the framingham offspring study. Diabetes Care 25:1313-1319.	
	109	MEIGS, J. B., D. E. Singer, L. M. Sullivan, K. A. Dukes, R. B. D'Agostino, D. M. Nathan, E. H. Wagner, S. H. Kaplan, and S. Greenfield. 1997. Metabolic control and prevalent cardiovascular disease in non-insulin-dependent diabetes mellitus (NIDDM): The NIDDM Patient Outcome Research Team. Am. J Med. 102:38-47.	
	110	MENETREY, J., C. Kasemkijwattana, C. S. Day, P. Bosch, M. Vogt, F. H. Fu, M. S. Moreland, and J. Huard. 2000. Growth factors improve muscle healing in vivo. J. Bone Joint Surg. Br. 82:131-137.	
	111	MIELE, C., J. J. Rochford, N. Filippa, S. Giorgetti-Peraldi, and E. Van Obberghen. 2000. Insulin and insulin-like growth factor-I induce vascular endothelial growth factor mRNA expression via different signaling pathways. J Biol. Chem. 275:21695-21702.	

Examiner  
SignatureDate  
Considered

3/11/2005

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 12 of 17 Sheets

**Complete if Known**

Application Number	10798,896
Filing Date	03/11/2004
First Named Inventor	Draghia-Akli, et al.
Group Art Unit	1632
Examiner Name	PAUL POWELL
Attorney Docket Number	AVSI-0034 (108328.00172)

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PO	112	MIKLAVCIC, D., K. Beravs, D. Semrov, M. Cemazar, F. Demsar, and G. Sersa. 1998. The importance of electric field distribution for effective in vivo electroporation of tissues. Biophys. J 74:2152-2158.	
	113	MONTARRAS, D., J. Chelly, E. Bober, H. Arnold, M. O. Ott, F. Gros, and C. Pinset. 1991. Developmental patterns in the expression of Myf5, MyoD, myogenin, and MRF4 during myogenesis. New Biol. 3:592-600.	
	114	MUMPER, R. J., J. Wang, S. L. Klakamp, H. Nitta, K. Anwer, F. Tagliaferri, and A. P. Rolland. 1998. Protective interactive noncondensing (PINC) polymers for enhanced plasmid distribution and expression in rat skeletal muscle. J. Control Release 52:191-203.	
	115	MURAMATSU, T., S. Arakawa, K. Fukazawa, Y. Fujiwara, T. Yoshida, R. Sasaki, S. Masuda, and H. M. Park. 2001. In vivo gene electroporation in skeletal muscle with special reference to the duration of gene expression. Int. J. Mol. Med. 7:37-42.	
	116	NAIRN, R. S., G. M. Adair, T. Porter, S. L. Pennington, D. G. Smith, J. H. Wilson, and M. M. Seidman. 1993. Targeting vector configuration and method of gene transfer influence targeted correction of the APRT gene in Chinese hamster ovary cells. Somat. Cell Mol. Genet. 19:363-375.	
	117	NARUM, D. L., S. Kumar, W. O. Rogers, S. R. Fuhrmann, H. Liang, M. Oakley, A. Taye, B. K. Sim, and S. L. Hoffman. 2001. Codon optimization of gene fragments encoding Plasmodium falciparum merzoite proteins enhances DNA vaccine protein expression and immunogenicity in mice. Infect. Immun. 69:7250-7253.	
	118	NEUMANN, E., M. Schaefer-Ridder, Y. Wang, and P. H. Hofschneider. 1982. Gene transfer into mouse lyoma cells by electroporation in high electric fields. EMBO J. 1:841-845.	
	119	NOMOTO, S., Y. Tatematsu, T. Takahashi, and H. Osada. 1999. Cloning and characterization of the alternative promoter regions of the human LIMK2 gene responsible for alternative transcripts with tissue-specific expression. Gene 236:259-271.	
	120	OHLSSON, H., S. Thor, and T. Edlund. 1991. Novel insulin promoter- and enhancer-binding proteins that discriminate between pancreatic alpha- and beta-cells. Mol. Endocrinol. 5:897-904.	
PO	121	OTANI, Y., Y. Tabata, and Y. Ikada. 1996. Rapidly curable biological glue composed of gelatin and poly(L-glutamic acid). Biomaterials 17:1387-1391.	

Examiner  
SignatureDate  
Considered

3/14/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 13 of 17 Sheets

**Complete if Known**

Application Number	10/798,896
Filing Date	03/11/2004
First Named Inventor	Draghia-Akli, et al.
Group Art Unit	1632
Examiner Name	PAUL POWELL
Attorney Docket Number	AVSI-0034 (108328.00172)

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PD	122	OTANI, Y., Y. Tabata, and Y. Ikada. 1998. Hemostatic capability of rapidly curable glues from gelatin, poly(L-glutamic acid), and carbodiimide. Biomaterials 19:2091-2098.	
	123	PECH, M., C. D. Rao, K. C. Robbins, and S. A. Aaronson. 1989. Functional identification of regulatory elements within the promoter region of platelet-derived growth factor 2. Mol. Cell Biol. 9:396-405.	
	124	PELLETIER, J. and N. Sonenberg. 1988. Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. Nature 334:320-325.	
	125	PETERS, K. G. 1998. Vascular endothelial growth factor and the angiopoietins: working together to build a better blood vessel. Circ. Res. 83:342-343.	
	126	PINKERT, C. A., D. M. Ornitz, R. L. Brinster, and R. D. Palmiter. 1987. An albumin enhancer located 10 kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice. Genes Dev. 1:268-276.	
	127	POTTER, H., L. Weir, and P. Leder. 1984. Enhancer-dependent expression of human kappa immunoglobulin genes introduced into mouse pre-B lymphocytes by electroporation. Proc. Natl. Acad. Sci. U. S. A 81:7161-7165.	
	128	PRENTICE, H., R. A. Kloner, T. Prigozy, T. Christensen, L. Newman, Y. Li, and L. Kedes. 1994. Tissue restricted gene expression assayed by direct DNA injection into cardiac and skeletal muscle. Journal of Molecular & Cellular Cardiology 26:1393-1401.	
	129	PUNGILIA, R. S., M. Lu, J. Hsu, M. Kuroki, M. J. Tolentino, K. Keough, A. P. Levy, N. S. Levy, M. A. Goldberg, R. J. D'Amato, and A. P. Adamis. 1997. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I. Diabetes 46:1619-1626.	
	130	RABINOVSKY, E. D., E. Gelir, S. Gelir, H. Lui, M. Kattash, F. J. DeMayo, S. M. Shenaq, and R. J. Schwartz. 2003. Targeted expression of IGF-I transgene to skeletal muscle accelerates muscle and motor neuron regeneration. FASEB J 17:53-55.	
	131	RANTANEN, J., T. Hurme, R. Lukka, J. Heino, and H. Kalimo. 1995. Satellite cell proliferation and the expression of myogenin and desmin in regenerating skeletal muscle: evidence for two different populations of satellite cells. Lab Invest 72:341-347.	

Examiner  
SignatureDate  
Considered

3/14/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 14 of 17 Sheets

**Complete if Known**

Application Number	10/798,896
Filing Date	03/11/2004
First Named Inventor	Draghia-Akli, et al.
Group Art Unit	1632
Examiner Name	Paul Dumez
Attorney Docket Number	AVSI-0034 (108328.00172)

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
DN	132	REINMUTH, N., F. Fan, W. Liu, A. A. Parikh, O. Stoeltzing, Y. D. Jung, C. D. Bucana, R. Radinsky, G. E. Gallick, and L. M. Ellis. 2002. Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest 82:1377-1389.	
	133	REISS, K., W. Cheng, A. Ferber, J. Kajstura, P. Li, B. Li, G. Olivetti, C. J. Homcy, R. Baserga, and P. Anversa. 1996. Overexpression of insulin-like growth factor-I in the heart is coupled with myocyte proliferation in transgenic mice. Proc. Natl. Acad. Sci. U. S. A 93:8630-8635.	
	134	REISS, K., J. Kajstura, X. Zhang, P. Li, E. Szoke, G. Olivetti, and P. Anversa. 1994. Acute myocardial infarction leads to upregulation of the IGF-I autocrine system, DNA replication, and nuclear mitotic division in the remaining viable cardiac myocytes. Exp. Cell Res. 213:463-472.	
	135	RIVARD, A., M. Silver, D. Chen, M. Kearney, M. Magner, B. Annex, K. Peters, and J. M. Isner. 1999. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am. J Pathol. 154:355-363.	
	136	SHIGEMATSU, S., K. Yamauchi, K. Nakajima, S. Iijima, T. Aizawa, and K. Hashizume. 1999. IGF-I regulates migration and angiogenesis of human endothelial cells. Endocr. J 46 Suppl:S59-62..S59-S62.	
	137	SILVESTRE, J.S., Levy, B.I., 2002. Angiogenesis therapy in ischemic disease. Arch. Mal Coeur Vaiss. 95, 189-196.	
	138	SJOGREN, K., J. O. Jansson, O. G. Isaksson, and C. Ohlsson. 2002. A transgenic model to determine the physiological role of liver-derived insulin-like growth factor I. Minerva Endocrinol. 27:299-311.	
	139	SJOGREN, K., J. L. Liu, K. Blad, S. Skrtic, O. Vidal, V. Wallenius, D. LeRoith, J. Tornell, O. G. Isaksson, J. O. Jansson, and C. Ohlsson. 1999. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc. Natl. Acad. Sci. U. S. A 96:7088-7092.	
	140	SKROCH, P., C. Buchman, and M. Karin. 1993. Regulation of human and yeast metallothionein gene transcription by heavy metal ions. Prog. Clin. Biol. Res. 380:113-28.:113-128.	
	141	SMITH, L. C. and J. L. Nordstrom. 2000. Advances in plasmid gene delivery and expression in skeletal muscle. Curr. Opin. Mol. Ther. 2:150-154.	

Examiner  
Signature

Date

Considered

3/14/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 15 of 17 Sheets

**Complete if Known**

Application Number	10/798,896
Filing Date	03/11/2004
First Named Inventor	Draghia-Akli, et al.
Group Art Unit	1632
Examiner Name	PAUL MONE
Attorney Docket Number	AVSI-0034 (108328.00172)

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PV	142	SONG, S., J. Embury, P. J. Laipis, K. I. Bems, J. M. Crawford, and T. R. Flotte. 2001. Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors. <i>Gene Ther.</i> 8:1299-1306.	
	143	SOUBRIER, F., B. Cameron, B. Manse, S. Somarriba, C. Dubertret, G. Jaslin, G. Jung, C. L. Caer, D. Dang, J. M. Mouvault, D. Scherman, J. F. Mayaux, and J. Crouzet. 1999. pCOR: a new design of plasmid vectors for nonviral gene therapy. <i>Gene Ther.</i> 6:1482-1488.	
	144	SPOERRI, P. E., E. A. Ellis, R. W. Tamuzzer, and M. B. Grant. 1998. Insulin-like growth factor: receptor and binding proteins in human retinal endothelial cell cultures of diabetic and non-diabetic origin. <i>Growth Horm. IGF. Res.</i> 8:125-132.	
	145	TERADA, Y., H. Tanaka, T. Okado, S. Inoshita, M. Kuwahara, T. Akiba, S. Sasaki, and F. Marumo. 2001. Efficient and ligand-dependent regulated erythropoietin production by naked dna injection and in vivo electroporation. <i>Am. J. Kidney Dis.</i> 38:S50-S53.	
	146	TONEGUZZO, F., A. Keating, S. Glynn, and K. McDonald. 1988. Electric field-mediated gene transfer: characterization of DNA transfer and patterns of integration in lymphoid cells. <i>Nucleic Acids Res.</i> 16:5515-5532.	
	147	TRIPATHY, S. K., E. C. Svensson, H. B. Black, E. Goldwasser, M. Margalith, Hobart, PM, and J. M. Leiden. 1996. Long-term expression of erythropoietin in the systemic circulation of mice after intramuscular injection of a plasmid DNA vector. <i>Proc. Natl. Acad. Sci. USA</i> 93:10876-10880.	
	148	TRONCHE, F., A. Rollier, I. Bach, M. C. Weiss, and M. Yaniv. 1989. The rat albumin promoter: cooperation with upstream elements is required when binding of APF/HNF1 to the proximal element is partially impaired by mutation or bacterial methylation. <i>Mol. Cell Biol.</i> 9:4759-4766.	
	149	TRONCHE, F., A. Rollier, P. Herbolme, I. Bach, S. Cereghini, M. Weiss, and M. Yaniv. 1990. Anatomy of the rat albumin promoter. <i>Mol. Biol. Med.</i> 7:173-185.	
	150	TRUDEL, M. and F. Costantini. 1987. A 3' enhancer contributes to the stage-specific expression of the human beta-globin gene. <i>Genes Dev.</i> 1:954-961.	
	151	TSUMAKI, N., T. Kimura, K. Tanaka, J. H. Kimura, T. Ochi, and Y. Yamada. 1998. Modular arrangement of cartilage- and neural tissue-specific cis-elements in the mouse alpha2(XI) collagen promoter. <i>J. Biol. Chem.</i> 273:22861-22864.	

Examiner  
SignatureDate  
Considered

3/14/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 16 of 17 Sheets

**Complete if Known**

Application Number	10/798,896
Filing Date	03/11/2004
First Named Inventor	Draghia-Akli, et al.
Group Art Unit	1632
Examiner Name	JAM DONEU
Attorney Docket Number	AVSI-0034 (108328.00172)

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PD	152	TSURUMI, Y., S. Takeshita, D. Chen, M. Kearney, S. T. Rossow, J. Passeri, J. R. Horowitz, J. F. Symes, and J. M. Isner. 1996. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion [see comments]. Circulation 94:3281-3290.	
	153	TUR-KASPA, R., L. Teicher, B. J. Levine, A. I. Skoultchi, and D. A. Shafritz. 1986. Use of electroporation to introduce biologically active foreign genes into primary rat hepatocytes. Mol. Cell Biol. 6:716-718.	
	154	VANCE, M. L. 1990. Growth-hormone-releasing hormone. [Review] [52 refs]. Clinical Chemistry 36:415-420.	
	155	VANDENBURGH, H. H., P. Karlisch, J. Shansky, and R. Feldstein. 1991. Insulin and IGF-I induce pronounced hypertrophy of skeletal myofibers in tissue culture. Am. J. Physiol. 260:C475-C484.	
	156	VEIKKOLA, T., M. Karkkainen, L. Claesson-Welsh, and K. Alitalo. 2000. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 60:203-212.	
	157	VILQUIN, J. T., P. F. Kennel, M. Patureau-Jouas, P. Chapdelaine, N. Boissel, P. Delaere, J. P. Tremblay, D. Scherman, M. Y. Fisman, and K. Schwartz. 2001. Electroporation of naked DNA in the skeletal muscles of animal models of muscular dystrophies. Gene Ther. 8:1097-1107.	
	158	WALSH, M. F., M. Barazi, G. Pete, R. Muniyappa, J. C. Dunbar, and J. R. Sowers. 1996. Insulin-like growth factor I diminishes in vivo and in vitro vascular contractility: role of vascular nitric oxide. Endocrinology 137:1798-1803.	
	159	WANG, L., W. Ma, R. Markovich, J. W. Chen, and P. H. Wang. 1998a. Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor I. Circ. Res. 83:516-522.	
	160	WANG, L., W. Ma, R. Markovich, W. L. Lee, and P. H. Wang. 1998b. Insulin-like growth factor I modulates induction of apoptotic signaling in H9C2 cardiac muscle cells. Endocrinology 139:1354-1360.	
PD	161	WELLS, K. E., J. Maule, R. Kingston, K. Foster, J. McMahon, E. Damien, A. Poole, and D. J. Wells. 1997. Immune responses, not promoter inactivation, are responsible for decreased long-term expression following plasmid gene transfer into skeletal muscle. FEBS Lett. 407:164-168.	

Examiner  
SignatureDate  
Considered

3/14/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 17 of 17 Sheets

**Complete If Known**

Application Number	10798,896
Filing Date	03/11/2004
First Named Inventor	Draghia-Akli, et al.
Group Art Unit	1632
Examiner Name	PAUL HOWELL
Attorney Docket Number	AVSI-0034 (108328.00172)

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PD	162	WOLFF, J. A., R. W. Malone, P. Williams, W. Chong, G. Acsadi, A. Jani, Felgner, and PL. 1990. Direct gene transfer into mouse muscle in vivo. Science 247:1465-1468.	
	163	WU, H. K., J. A. Squire, Q. Song, and R. Weksberg. 1997. Promoter-dependent tissue-specific expressive nature of imprinting gene, insulin-like growth factor II, in human tissues. Biochem. Biophys. Res. Commun. 233:221-226.	
	164	WU, Y., S. Yakar, L. Zhao, L. Hennighausen, and D. LeRoith. 2002. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res. 62:1030-1035.	
	165	XIE, T. D. and T. Y. Tsong. 1993. Study of mechanisms of electric field-induced DNA transfection. V. Effects of DNA topology on surface binding, cell uptake, expression, and integration into host chromosomes of DNA in the mammalian cell. Biophys. J. 65:1684-1689.	
	166	YASUI, A., K. Oda, H. Usunomiya, K. Kakudo, T. Suzuki, T. Yoshida, H. M. Park, K. Fukazawa, and T. Muramatsu. 2001. Elevated gastrin secretion by in vivo gene electroporation in skeletal muscle. Int. J Mol. Med. 8:489-494.	
	167	YIN, D. and J. G. Tang. 2001. Gene therapy for streptozotocin-induced diabetic mice by electroporation transfer of naked human insulin precursor DNA into skeletal muscle in vivo. FEBS Lett. 495:16-20.	
	168	YORIFUJI, T. and H. Mikawa. 1990. Co-transfer of restriction endonucleases and plasmid DNA into mammalian cells by electroporation: effects on stable transformation. Mutat. Res. 243:121-126.	
	169	YUTZEY, K. E. and S. F. Konieczny. 1992. Different E-box regulatory sequences are functionally distinct when placed within the context of the troponin I enhancer. Nucleic Acids Res. 20:5105-5113.	
	170	ZHAO-EMONET, J. C., O. Boyer, J. L. Cohen, and D. Klatzmann. 1998. Deletional and mutational analyses of the human CD4 gene promoter: characterization of a minimal tissue-specific promoter. Biochem Biophys. Acta 1442:109-119.	
PD	171	ZHUANG, H. X., C. K. Snyder, S. F. Pu, and D. N. Ishii. 1996. Insulin-like growth factors reverse or arrest diabetic neuropathy: effects on hyperalgesia and impaired nerve regeneration in rats. Exp. Neurol. 140:198-205.	

Examiner  
SignatureDate  
Considered

3/14/2003

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet	1	of	2 Sheets
-------	---	----	----------

**Complete if Known**

Application Number	10/798,896
Filing Date	03/11/2004
First Named Inventor	Draghia-Akli, et al.
Group Art Unit	1632
Examiner Name	Paul Powell
Attorney Docket Number	AVSI-0034 (108328.00172)

[illegible]

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>1</sup> - Kind Code <sup>5</sup> (if known)				

*[Handwritten signature]*

3/4/2006

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313.**



AVSI-00034 (108328.00172)

PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2 Sheets

**Complete if Known**

Application Number	10/798,896
Filing Date	03/11/2004
First Named Inventor	Draghia-Akli, et al.
Group Art Unit	1692
Examiner Name	PAUL OSWELL
Attorney Docket Number	AVSI-0034 (108328.00172)

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PO	2	RABINOVSKY E. D., Draghia-Akli R., Insulin-Like Growth Factor I Plasmid Therapy Promotes in vivo Angiogenesis. Molecular Therapy Vol 9, No. 1, p 46-54 (2004).	
PO	3	International Search Report, International Application No. PCT/US 04/007295, August 8, 2004	

Examiner  
SignatureDate  
Considered

3/11/2004

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet	1	of	1 Sheets
-------	---	----	----------

**Complete if Known**

Application Number	10/798,896
Filing Date	03/11/2004
First Named Inventor	Draghia-Akli, et al.
Group Art Unit	1622
Examiner Name	Paul Bowser
Attorney Docket Number	AVSI-0034 (108328.00172)

#### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

[illegible]

**Examiner  
Signature**

Date Considered

3/14/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the complexity of the information provided.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313.**